The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Sep 28

PMID 37765052

Authors

Martin Rakusa

Jeremy Chataway

Todd A Hardy

Affiliations

Soon will be listed here.

Abstract

Background: We assessed the prevalence and risks associated with pain during and after a multiple sclerosis (MS) relapse, and the impact of pain on quality of life (QoL), in MS patients.

Methods: 117 patients suffering an acute MS relapse were evaluated with clinician- and patient-reported outcomes, including the expanded disability status scale (EDSS), Multiple Sclerosis Impact Scale (MSIS-29), and MS Walking scale-12 (MSWS-12). Relapse-related pain was assessed via the short-form 36 (SF-36) questionnaire upon first visit (relapse onset) and at 6 weeks after treatment with intravenous methylprednisolone (follow-up visit).

Results: Pain was present in 80% of patients at relapse onset. Patients with pain were more impaired physically (higher mean scores on MSIS-29 and MSWS-12 and lower mean scores on SF-36 role physical, physical, and vitality scales) at relapse and six weeks after. In total, 74% of patients with MS relapse reported a poorer QoL due to pain. A lower psychological well-being was correlated with greater pain (MSIS29 score). An increased number of prior relapses was a predictor of more pain at relapse onset.

Conclusions: Pain was common at the time of MS relapse and improved, but was still significant, six weeks after treatment with corticosteroids. Further studies are required to better understand relapse-related pain.

References

Bacher Svendsen K, Jensen T, Overvad K, Hansen H, Koch-Henriksen N, Bach F . Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003; 60(8):1089-94. DOI: 10.1001/archneur.60.8.1089. View

Bowling A, Bond M, Jenkinson C, Lamping D . Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Healthy Life Survey. J Public Health Med. 1999; 21(3):255-70. DOI: 10.1093/pubmed/21.3.255. View

Martinelli Boneschi F, Colombo B, Annovazzi P, Martinelli V, Bernasconi L, Solaro C . Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008; 14(4):514-21. DOI: 10.1177/1352458507085551. View

Young J, Amatya B, Galea M, Khan F . Chronic pain in multiple sclerosis: A 10-year longitudinal study. Scand J Pain. 2017; 16:198-203. DOI: 10.1016/j.sjpain.2017.04.070. View

Spain L, Tubridy N, Kilpatrick T, Adams S, Holmes A . Illness perception and health-related quality of life in multiple sclerosis. Acta Neurol Scand. 2007; 116(5):293-9. DOI: 10.1111/j.1600-0404.2007.00895.x. View

Moulin D, Foley K, Ebers G . Pain syndromes in multiple sclerosis. Neurology. 1988; 38(12):1830-4. DOI: 10.1212/wnl.38.12.1830. View

Mitchell A, Benito-Leon J, Gonzalez J, Rivera-Navarro J . Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005; 4(9):556-66. DOI: 10.1016/S1474-4422(05)70166-6. View

Sander L, Kugler J, Elsner B . [The influence of multiple sclerosis-related symptoms on health-related quality of life]. Fortschr Neurol Psychiatr. 2020; 88(11):704-712. DOI: 10.1055/a-1113-7702. View

Rakusa M, Cano S, Porter B, Riazi A, Thompson A, Chataway J . A predictive model for corticosteroid response in individual patients with MS relapses. PLoS One. 2015; 10(3):e0120829. PMC: 4364957. DOI: 10.1371/journal.pone.0120829. View

10.

Truini A, Aleksovska K, Anderson C, Attal N, Baron R, Bennett D . Joint European Academy of Neurology-European Pain Federation-Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment. Eur J Neurol. 2023; 30(8):2177-2196. DOI: 10.1111/ene.15831. View

11.

Forbes A, While A, Mathes L, Griffiths P . Health problems and health-related quality of life in people with multiple sclerosis. Clin Rehabil. 2006; 20(1):67-78. DOI: 10.1191/0269215506cr880oa. View

12.

Janardhan V, Bakshi R . Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002; 205(1):51-8. DOI: 10.1016/s0022-510x(02)00312-x. View

13.

Zhao Z, Zhang Y, Du Q, Chen H, Shi Z, Wang J . Differences in physical, mental, and social functions between males and females in multiple sclerosis: A multicenter cross-sectional study in China. Mult Scler Relat Disord. 2021; 48:102693. DOI: 10.1016/j.msard.2020.102693. View

14.

Michalski D, Liebig S, Thomae E, Hinz A, Then Bergh F . Pain in patients with multiple sclerosis: a complex assessment including quantitative and qualitative measurements provides for a disease-related biopsychosocial pain model. J Pain Res. 2011; 4:219-25. PMC: 3160835. DOI: 10.2147/JPR.S20309. View

15.

Heitmann H, Haller B, Tiemann L, Muhlau M, Berthele A, Tolle T . Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain. 2020; 161(4):787-796. DOI: 10.1097/j.pain.0000000000001767. View

16.

OConnor A, Schwid S, Herrmann D, Markman J, Dworkin R . Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2007; 137(1):96-111. DOI: 10.1016/j.pain.2007.08.024. View

17.

Gil-Gonzalez I, Martin-Rodriguez A, Conrad R, Perez-San-Gregorio M . Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020; 10(11):e041249. PMC: 7705559. DOI: 10.1136/bmjopen-2020-041249. View

18.

Silva J, de Oliveira B, Nascimento O, Farinhas J, Cavaliere M, Cal H . Increased multiple sclerosis relapses related to lower prevalence of pain. Arq Neuropsiquiatr. 2015; 73(7):593-600. DOI: 10.1590/0004-282X20150073. View

19.

Tedman B, Young C, Williams I . Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. J Neurol Sci. 1998; 152 Suppl 1:S75-9. DOI: 10.1016/s0022-510x(97)00249-9. View

20.

Burholt V, Nash P . Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. J Public Health (Oxf). 2011; 33(4):587-603. DOI: 10.1093/pubmed/fdr006. View